Sign in to edit your profile (add interests, mentoring, photo, etc.)

    Brad Hare, MD

    TitleAssociate Clinical Professor
    SchoolUCSF School of Medicine
    DepartmentMedicine
    AddressSFGH Bldg 80
    Phone415-476-4082x556
    vCardDownload vCard

      Collapse Overview 
      Collapse Overview
      C. Bradley Hare, MD is Associate Professor of Clinical Medicine and Medical Director, UCSF HIV/AIDS Division at San Francisco General Hospital.

      Research Interests: Dr. Hare conducts patient-based research on a variety of topics important to HIV clinical management, the inspiration for which comes directly from observations in the clinic. Current areas of focus include HIV and Hepatitis C Virus (HCV) co-infection, where he studies the epidemiology, natural history and treatment of acute hepatitis C infection, the use of novel agents in the treatment of HIV-HCV co-infection, and models of HCV treatment in primary care settings. He also conducts research on HIV testing in medical settings such as the Emergency Department, linkage to care after HIV testing, and implementation of a patient-centered medical home for people aging with HIV infection.


      Collapse ORNG Applications 
      Collapse Websites
      Collapse In The News
      Collapse NIH Awarded Grants
      Collapse Global Health

      Collapse Bibliographic 
      Collapse Publications
      Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
      List All   |   Timeline
      1. Christopoulos KA, Zetola NM, Klausner JD, Haller B, Louie B, Hare CB, Pandori M, Nassos P, Roemer M, Pilcher CD. Leveraging a rapid, round-the-clock HIV testing system to screen for acute HIV infection in a large urban public medical center. J Acquir Immune Defic Syndr. 2013 Feb 1; 62(2):e30-8.
        View in: PubMed
      2. Geng EH, Hare CB, Kahn JO, Jain V, Van Nunnery T, Christopoulos KA, Deeks SG, Gandhi M, Havlir DV. The effect of a "universal antiretroviral therapy" recommendation on HIV RNA levels among HIV-infected patients entering care with a CD4 count greater than 500/┬ÁL in a public health setting. Clin Infect Dis. 2012 Dec; 55(12):1690-7.
        View in: PubMed
      3. Hoover KW, Butler M, Workowski KA, Follansbee S, Gratzer B, Hare CB, Johnston B, Theodore JL, Tao G, Smith BD, Chorba T, Kent CK. Low rates of hepatitis screening and vaccination of HIV-infected MSM in HIV clinics. Sex Transm Dis. 2012 May; 39(5):349-53.
        View in: PubMed
      4. Hogan CM, Degruttola V, Sun X, Fiscus SA, Del Rio C, Hare CB, Markowitz M, Connick E, Macatangay B, Tashima KT, Kallungal B, Camp R, Morton T, Daar ES, Little S. The setpoint study (ACTG A5217): effect of immediate versus deferred antiretroviral therapy on virologic set point in recently HIV-1-infected individuals. J Infect Dis. 2012 Jan 1; 205(1):87-96.
        View in: PubMed
      5. Markowitz M, Vaida F, Hare CB, Boden D, Mohri H, Hecht FM, Kalayjian RC, Conrad A, Mildvan D, Aberg J, Hogan C, Kilby JM, Balfour HH, Schafer K, Richman D, Little S. The virologic and immunologic effects of cyclosporine as an adjunct to antiretroviral therapy in patients treated during acute and early HIV-1 infection. J Infect Dis. 2010 May 1; 201(9):1298-302.
        View in: PubMed
      6. Tice AD, Bannan M, Bauman K, Collis T, Hall A, Haning W, Hannemann S, Hare CB, Humphry J, Jao R, Leevy C, Lusk H, Ochoa E, Palafox N, Withers N, Akinaka K. Viral hepatitis in Hawai'i--differing perspectives. Hawaii Med J. 2010 Apr; 69(4 Suppl 1):3-20.
        View in: PubMed
      7. Pilcher CD, Hare CB. The deadliest catch: fishing for HIV in new waters. Ann Intern Med. 2008 Aug 5; 149(3):204-5.
        View in: PubMed
      8. Petroll AE, Hare CB, Pinkerton SD. The essentials of HIV: a review for nurses. J Infus Nurs. 2008 Jul-Aug; 31(4):228-35.
        View in: PubMed
      9. Shoptaw S, Klausner JD, Reback CJ, Tierney S, Stansell J, Hare CB, Gibson S, Siever M, King WD, Kao U, Dang J. A public health response to the methamphetamine epidemic: the implementation of contingency management to treat methamphetamine dependence. BMC Public Health. 2006; 6:214.
        View in: PubMed
      10. Borucki M, Holodniy M, Pierone G, Ruane P, Steinhart C, Williams S, Slom T, Palella F, Hare CB, Yoshidao Y, Li XD, Pollard RB. The safety and tolerability of Z-100 in patients infected with HIV-1. Antivir Ther. 2006; 11(3):297-303.
        View in: PubMed
      11. Coggins CA, Elion GB, Houghton PJ, Hare CB, Keir S, Colvin OM, Bigner DD, Friedman HS. Enhancement of irinotecan (CPT-11) activity against central nervous system tumor xenografts by alkylating agents. Cancer Chemother Pharmacol. 1998; 41(6):485-90.
        View in: PubMed
      12. Hare CB, Elion GB, Houghton PJ, Houghton JA, Keir S, Marcelli SL, Bigner DD, Friedman HS. Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin against pediatric and adult central nervous system tumor xenografts. Cancer Chemother Pharmacol. 1997; 39(3):187-91.
        View in: PubMed
      13. Hare CB, Elion GB, Colvin OM, Ali-Osman F, Griffith OW, Petros WP, Keir S, Marcelli SL, Bigner DD, Friedman HS. Characterization of the mechanisms of busulfan resistance in a human glioblastoma multiforme xenograft. Cancer Chemother Pharmacol. 1997; 40(5):409-14.
        View in: PubMed
      Brad's Networks
      Related Concepts
      Derived automatically from this person's publications.
      _
      Co-Authors
      People in Profiles who have published with this person.
      _
      Related Authors
      People who share related concepts with this person.
      _
      Back to TOP